MicroRNA expression in acute myeloid leukemia
- First Online:
- 199 Downloads
Acute myeloid leukemia (AML) is a group of diseases that are very heterogeneous with regard to cytogenetic aberrations, gene mutations, and changes in expression of numerous genes. A new class of genes known as microRNAs recently was found to be involved in myeloid leukemogenesis. These genes are transcribed into regulatory, noncoding RNAs that control mRNA and protein expression of target genes. Genome-wide analyses of microRNA expression have revealed signatures associated with selected cytogenetic and molecular subsets of AML and have led to the recognition of previously unreported molecular pathways involved in myeloid leukemogenesis. In cytogenetically normal AML, microRNA-expression profiling has also provided prognostic information in addition to that obtained from cytogenetics and analyses of gene mutations and aberrant gene expression. This article reviews recent studies that were focused on the alterations of microRNA expression in AML and their diagnostic and prognostic significance.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Ries LAG, Melbert D, Krapcho M, et al. (eds): SEER Cancer Statistics Review, 1975–2005. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2005/.
- 7.Arber DA, Vardiman JW, Brunning RD, et al.: Acute myeloid leukaemia with recurrent genetic abnormalities. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Edited by Swerdlow SH, Campo E, Harris NL, et al. Lyon: IARC Press; 2008:110–123.Google Scholar
- 9.Mrózek K, Bloomfield CD: Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2006, 169–177.Google Scholar
- 11.Byrd JC, Mrózek K, Dodge RK, et al.: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325–4336.PubMedCrossRefGoogle Scholar
- 14.Virappane P, Gale R, Hills R, et al.: Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008, 26:5429–5435.PubMedCrossRefGoogle Scholar
- 15.Marcucci G, Maharry K, Whitman SP, et al.: High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2007, 25:3337–3343.PubMedCrossRefGoogle Scholar
- 16.Langer C, Radmacher MD, Ruppert AS, et al.: High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008, 111:5371–5379.PubMedCrossRefGoogle Scholar
- 42.Marcucci G, Maharry K, Radmacher MD, et al.: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol 2008, 26:5078–5087.PubMedCrossRefGoogle Scholar